MedTrace Logo

Pilot Study of Reduced Venetoclax Exposure

NCT07163793 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-11-20

No results posted yet for this study

Summary

Pilot Study of Reduced Venetoclax Exposure

Conditions

  • Acute Myeloid Leukemia in Remission

Interventions

DRUG

Azacitidine

Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study

DRUG

Decitabine

Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off

DRUG

Venetoclax

Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Boiclair Stephanie, MD · Northwell Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2026-10-31
Completion
2028-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163793 on ClinicalTrials.gov